Molecular Targeting Technologies, Inc. (MTTI), USA and Evergreen Theragnostics, Inc., USA recently announced an agreement in which Evergreen will manufacture MTTI's EvaThera™ platform of radiopharmaceuticals.
Evergreen
will manufacture MTTI clinical supplies from its newly commissioned facility in
Springfield, NJ and will leverage the team's broad experience with Lu-177 based
radiotherapeutics by providing comprehensive supply chain management from
isotope sourcing to drug delivery at the clinical trial site.
To
read more please visit:
MTTI
partners with Evergreen to Manufacture EvaThera Platform of
Radiopharmaceuticals
Source: MTTI